Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 4/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017008 | 1.00 | FPR2 (0.51) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL475961 | 0.87 | FOLH1 (0.54) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL27669241 | 0.87 | FPR2 (0.49) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL475962 | 0.87 | FOLH1 (0.54) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL27669242 | 0.87 | FPR2 (0.49) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL9809605 | 0.85 | MME (0.51) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL9809609 | 0.85 | MME (0.51) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL6130477 | 0.85 | MME (0.51) | FPR2MMENPSR1NAALAD2CYP1A2 | |
| SCHEMBL7211707 | 0.85 | MME (0.51) | FPR2MMENPSR1NAALAD2CYP1A2 | |
| SCHEMBL6130478 | 0.85 | MME (0.51) | FPR2MMENPSR1NAALAD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4117732-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Ambrx, Inc. (US) | 2023-01-18 | — | — | EP | claimed |
| WO-2021183832-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2021-09-16 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| EP-0644772-A4 | OPIOID PEPTIDES. | BIOMEASURE INC (US) | 1997-01-29 | — | — | EP | claimed |
| EP-0644772-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1995-03-29 | — | — | EP | claimed |
| WO-1994011018-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-7569730-B2 | Bisphosphine ligand | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080242534-A1 | NOVEL BISPHOSPHINE LIGAND | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2008-10-02 | — | — | US | disclosed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0644772-A4 | OPIOID PEPTIDES. | BIOMEASURE INC (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
| EP-0644772-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994011018-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242534-A1 | NOVEL BISPHOSPHINE LIGAND | GPR4, HRH4, GPR3 | FPR2 1398/4885MME 4429/4885ACE 4080/4885 |
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | FPR2 3104/4885MME 37/4885ACE 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.